Menu Search
Equities

Q32 Bio Inc

DB0:MUN

Q32 Bio Inc

Actions
  • Price (EUR)44.20
  • Today's Change0.00 / 0.00%
  • Shares traded64.00
  • 1 Year change+155.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-65.02m
  • Incorporated2015
  • Employees41.00
  • Location
    Q32 Bio Inc830 Winter StreetWALTHAM 02451United StatesUSA
  • Phone+1 (781) 999-0232
  • Fax+1 (302) 655-5049
  • Websitehttps://www.q32bio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		QTTB:NMQ since
announced		Transaction
value
Q32 Bio IncDeal completed16 Nov 202316 Nov 2023Deal completed185.92%--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.